BioInvent to Host Virtual KOL Event on June 18, 2024, for Discussing Lead Candidates BI-1808 and BI-1206

BioInvent International AB (Nasdaq Stockholm: BINV), a pioneering biotech firm situated in Lund, Sweden, is advancing the field of cancer immunotherapy with a focus on immune-modulatory antibodies. The company is organizing a virtual Key Opinion Leader (KOL) event on June 18, 2024, from 9:00-10:45 AM ET/3:00-4:45 PM CEST. This session will provide an in-depth discussion on the clinical efficacy and safety data of BioInvent's lead drug candidates, BI-1808 and BI-1206, alongside the potential of TNFR2 and FcyRIIB as key targets in immuno-oncology.

BioInvent's core mission revolves around developing innovative, first-in-class antibodies that modulate the immune system to combat cancer. The company boasts a robust pipeline, currently featuring five drug candidates engaged in six Phase 1/2 clinical trials aimed at treating both hematological cancers and solid tumors. Key among these candidates are BI-1808 and BI-1206, which have shown promising clinical outcomes as reported in recent studies. TNFR2 and FcyRIIB have also emerged as significant targets for further research in the field of immuno-oncology.

A unique aspect of BioInvent's approach is its proprietary F.I.R.S.T™ technology platform, an advanced system that facilitates the identification of both novel targets and the antibodies that effectively bind to them. This platform has been instrumental in accelerating the discovery and development of numerous promising immune-modulatory candidates, bolstering BioInvent's clinical development pipeline and creating numerous opportunities for licensing and partnerships.

BioInvent's business model is multifaceted, generating revenue through research collaborations and licensing agreements with leading pharmaceutical companies. Additionally, the company operates a fully integrated manufacturing unit dedicated to producing antibodies for third-party clients. This comprehensive approach not only advances BioInvent’s own research but also supports the broader pharmaceutical industry by offering high-quality antibody production services.

In summary, BioInvent's upcoming virtual KOL event on June 18, 2024, will be an essential platform for discussing the latest clinical data on its leading drug candidates and exploring the potential of novel immuno-oncology targets. This event underscores the company's commitment to pioneering innovative cancer therapies and its role as a significant player in the biotechnology landscape.